Syntonix Pharmaceuticals Inc. agreed to out-license overseas rights to FIX:Fc, its preclinical recombinant Factor IX product for hemophilia B, to Biovitrum AB. (BioWorld Today)

Syntonix Pharmaceuticals Inc. agreed to out-license overseas rights to FIX:Fc, its preclinical recombinant Factor IX product for hemophilia B, to Biovitrum AB. (BioWorld Today)

Avigen Inc. is expanding its portfolio by way of an in-licensing deal that brings in tolperisone (AV650), a small molecule for disabling neuromuscular conditions, further distancing itself from its past as a gene therapy firm. (BioWorld Today)

Avigen Inc. is expanding its portfolio by way of an in-licensing deal that brings in tolperisone (AV650), a small molecule for disabling neuromuscular conditions, further distancing itself from its past as a gene therapy firm. (BioWorld Today)